Vicore Pharma Holding AB
corporate_fare Company Profile
Vicore Pharma Holding AB (NASDAQ:VCRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for VCRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-21, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for VCRE spans 6-K.
Recent high-impact activity:
- Vicore Pharma Posts Q2 Loss, Completes ASPIRE Enrollment, and Extends Cash Runway to 2028
- Vicore Pharma Appoints Former GSK VP Rob Slack as Chief Scientific Officer
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 9,857 shares in VCRE as of the September 15, 2026 settlement, a 15.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 72.0% of VCRE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
VCRE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.